(Q39827858)

15 September 2017

title

Biomarkers in Parkinson's disease: a funder's perspective (English)

1 reference

15 September 2017

Biomarkers in Parkinson‘s Disease: A Funder‘s Perspective (English)

1 reference

2 August 2024

0 references

1 reference

Mark Frasier

1

1 reference

15 September 2017

Sohini Chowdhury

2

1 reference

15 September 2017

Jamie Eberling

3

1 reference

15 September 2017

Todd Sherer

4

1 reference

15 September 2017

language of work or name

English

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=20945984

2 August 2024

publication date

1 October 2010

1 reference

full work available at URL

15 September 2017

http://www.futuremedicine.com/doi/abs/10.2217/bmm.10.89

online access status

open access

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20945984

https://www.tandfonline.com/doi/pdf/10.2217/bmm.10.89

2 August 2024

1 reference

2 August 2024

published in

Biomarkers in Medicine

1 reference

15 September 2017

volume

4

1 reference

15 September 2017

issue

5

1 reference

15 September 2017

page(s)

723-729

1 reference

A responsive outcome for Parkinson's disease neuroprotection futility studies

15 September 2017

cites work

1 reference

Direct quantification of CSF alpha-synuclein by ELISA and first cross-sectional study in patients with neurodegeneration

21 January 2018

1 reference

Molecular markers of early Parkinson's disease based on gene expression in blood

21 January 2018

1 reference

Metabolomic profiling to develop blood biomarkers for Parkinson's disease

21 January 2018

1 reference

Five-year follow-up study of hyperechogenicity of the substantia nigra in Parkinson's disease

21 January 2018

1 reference

Enlarged hyperechogenic substantia nigra is related to motor performance and olfaction in the elderly

21 January 2018

1 reference

Biological and clinical manifestations of Huntington's disease in the longitudinal TRACK-HD study: cross-sectional analysis of baseline data

21 January 2018

1 reference

Cerebrospinal fluid abnormalities and rate of decline in everyday function across the dementia spectrum: normal aging, mild cognitive impairment, and Alzheimer disease

21 January 2018

1 reference

Biomarker discovery for Alzheimer's disease, frontotemporal lobar degeneration, and Parkinson's disease

21 January 2018

1 reference

Validation and comparison of two multiplex technologies, Luminex and Mesoscale Discovery, for human cytokine profiling

21 January 2018

1 reference

Role of DAT-SPECT in the diagnostic work up of parkinsonism

21 January 2018

1 reference

The role of DAT-SPECT in movement disorders

21 January 2018

1 reference

High-resolution diffusion tensor imaging in the substantia nigra of de novo Parkinson disease

21 January 2018

1 reference

Multimodal techniques for diagnosis and prognosis of Alzheimer's disease

21 January 2018

1 reference

Biomarkers for Alzheimer's disease: academic, industry and regulatory perspectives

21 January 2018

1 reference

Cerebrospinal fluid alpha-synuclein in neurodegenerative disorders-a marker of synapse loss?

21 January 2018

1 reference

DJ-1 and alpha-synuclein in human cerebrospinal fluid as biomarkers of Parkinson's disease

21 January 2018

1 reference

Decreased alpha-synuclein in cerebrospinal fluid of aged individuals and subjects with Parkinson's disease

21 January 2018

1 reference

Quantitative proteomic analysis of age-related changes in human cerebrospinal fluid

21 January 2018

1 reference

Preparation and application of monoclonal antibodies against oxidized DJ-1. Significant elevation of oxidized DJ-1 in erythrocytes of early-stage Parkinson disease patients

21 January 2018

1 reference

Serum uric acid levels in patients with Parkinson's disease: their relationship to treatment and disease duration.

21 January 2018

1 reference

Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B

21 January 2018

1 reference

In vivo imaging of amyloid deposition in Alzheimer disease using the radioligand 18F-AV-45 (florbetapir [corrected] F 18)

21 January 2018

1 reference

In vivo measurement of vesicular monoamine transporter type 2 density in Parkinson disease with (18)F-AV-133

21 January 2018

1 reference

Early differential diagnosis of Parkinson's disease with 18F-fluorodeoxyglucose and positron emission tomography.

21 January 2018

1 reference

[11C]raclopride and positron emission tomography in previously untreated patients with Parkinson's disease: Influence of L-dopa and lisuride therapy on striatal dopamine D2-receptors

21 January 2018

1 reference

In vivo imaging of microglial activation with [11C](R)-PK11195 PET in idiopathic Parkinson's disease

21 January 2018

1 reference

Inner retinal layer thinning in Parkinson disease.

21 January 2018

1 reference

Mixed lineage kinase inhibitor CEP-1347 fails to delay disability in early Parkinson disease.

21 January 2018

1

1 reference

Ways toward an early diagnosis in Alzheimer's disease: the Alzheimer's Disease Neuroimaging Initiative (ADNI).

2 August 2024

10

1 reference

Detection of oligomeric forms of alpha-synuclein protein in human plasma as a potential biomarker for Parkinson's disease

2 August 2024

20

1 reference

A more efficient enzyme-linked immunosorbent assay for measurement of alpha-synuclein in cerebrospinal fluid

2 August 2024

23

1 reference

Sensitive and specific detection of α-synuclein in human plasma

2 August 2024

25

1 reference

Correlation between DJ-1 levels in the cerebrospinal fluid and the progression of disabilities in multiple sclerosis patients

2 August 2024

28

1 reference

Decreased myocardial 123I-MIBG uptake in Parkinson's disease

2 August 2024

39

1 reference

2 August 2024

Identifiers

DOI

10.2217/BMM.10.89

1 reference

15 September 2017

1 reference